Free Trial
NASDAQ:IPA

ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

ImmunoPrecise Antibodies logo
$1.64 -0.02 (-1.20%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.69 +0.05 (+3.05%)
As of 07:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)

Key Stats

Today's Range
$1.52
$1.64
50-Day Range
$0.53
$2.31
52-Week Range
$0.27
$2.41
Volume
1.01 million shs
Average Volume
2.19 million shs
Market Capitalization
$75.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

ImmunoPrecise Antibodies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

IPA MarketRank™: 

ImmunoPrecise Antibodies scored higher than 40% of companies evaluated by MarketBeat, and ranked 666th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ImmunoPrecise Antibodies has received no research coverage in the past 90 days.

  • Read more about ImmunoPrecise Antibodies' stock forecast and price target.
  • Earnings Growth

    Earnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.27) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmunoPrecise Antibodies is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmunoPrecise Antibodies is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ImmunoPrecise Antibodies has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ImmunoPrecise Antibodies' valuation and earnings.
  • Percentage of Shares Shorted

    1.25% of the float of ImmunoPrecise Antibodies has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmunoPrecise Antibodies has recently increased by 114.54%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ImmunoPrecise Antibodies does not currently pay a dividend.

  • Dividend Growth

    ImmunoPrecise Antibodies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.25% of the float of ImmunoPrecise Antibodies has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmunoPrecise Antibodies has recently increased by 114.54%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ImmunoPrecise Antibodies has a news sentiment score of -0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for ImmunoPrecise Antibodies this week, compared to 1 article on an average week.
  • Search Interest

    13 people have searched for IPA on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.

  • Percentage Held by Institutions

    Only 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.

  • Read more about ImmunoPrecise Antibodies' insider trading history.
Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

IPA Stock News Headlines

HC Wainwright Issues Negative Outlook for IPA Earnings
Market Crash Warning: How to Protect Your Wealth Before August 12th
China tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alternative Assets reveals 3 urgent moves to protect your portfolio, plus the #1 asset class thriving during crises (hint: it’s not stocks or bonds).
See More Headlines

IPA Stock Analysis - Frequently Asked Questions

ImmunoPrecise Antibodies' stock was trading at $0.4117 on January 1st, 2025. Since then, IPA shares have increased by 298.3% and is now trading at $1.64.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its earnings results on Tuesday, July, 29th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. The firm earned $5.06 million during the quarter, compared to analysts' expectations of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative trailing twelve-month return on equity of 40.62%.
Read the conference call transcript
.

ImmunoPrecise Antibodies' top institutional investors include Ingalls & Snyder LLC (6.07%) and Baader Bank Aktiengesellschaft (0.06%).

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/29/2025
Today
8/04/2025
Next Earnings (Estimated)
9/15/2025
Fiscal Year End
4/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IPA
CIK
1715925
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$3.00
Potential Upside/Downside
+143.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.69 million
Net Margins
-122.10%
Pretax Margin
-139.75%
Return on Equity
-40.62%
Return on Assets
-22.19%

Debt

Debt-to-Equity Ratio
0.49
Current Ratio
2.08
Quick Ratio
1.85

Sales & Book Value

Annual Sales
$17.59 million
Price / Sales
4.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.37 per share
Price / Book
4.43

Miscellaneous

Outstanding Shares
46,150,000
Free Float
43,002,000
Market Cap
$75.69 million
Optionable
Not Optionable
Beta
0.49
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IPA) was last updated on 8/4/2025 by MarketBeat.com Staff
From Our Partners